ALCON N | 63.86 / +2.11% |
Date/Time | 03/01 / 13:17 |
Chg. / Chg.(%) | 1.32 / +2.11% |
Bid | 63.86 / 76 |
Ask | 63.88 / 361 |
Open | 62.58 |
Previous Close | 62.54 |
High | 64.48 |
Low | 62.58 |
Volume [CHF] | 20,713,713.45 |
Volume [Units] | 324,734 |
Price fixings | 2520 |
ISIN | CH0432492467 |
Security | ALC |
Exchange | SIX Swiss Exchange |
Type | Stock |
Bid Size | Bid | Ask | Ask size |
---|---|---|---|
76 | 63.86 | 63.88 | 361 |
931 | 63.84 | 63.90 | 1,418 |
1,442 | 63.82 | 63.92 | 1,148 |
2,211 | 63.80 | 63.94 | 1,556 |
1,779 | 63.78 | 63.96 | 692 |
1,692 | 63.76 | 63.98 | 1,544 |
2,569 | 63.74 | 64.00 | 2,047 |
1,977 | 63.72 | 64.02 | 297 |
1,218 | 63.70 | 64.04 | 2,388 |
2,003 | 63.68 | 64.06 | 2,217 |
News
- Ed TALKS Panel: SolariGate – Avoiding Supply Chain Burns
02/18/2021 / 16:15 - GlobeNewswire - ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
02/16/2021 / 22:30 - GlobeNewswire - UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
02/01/2021 / 14:00 - GlobeNewswire - Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
02/01/2021 / 13:30 - GlobeNewswire - ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
12/22/2020 / 13:00 - GlobeNewswire